Yet another MS has been accepted for publication by our group. Its in:
Experimental and Clinical Endocrinology & Diabetes - Decision on Manuscript ID ECED-09-2017-0341-Endocrinology-Art.R1
This paper isn't yet available but I summarise its findings. It has studied patients on T4 therapy (cannot do it on joint therapy because of confounding by T3 dosage) over up to 9 years. These patients have routinely come for consultation and discussion with a doctor and separate endocrinologist to monitor their progress and health under continuous therapy and to adjust dosage according to presentation. The important thing was to record all instances of "hypothyroid symptoms" complaints given voluntarily by the patients on consultation and relate them to either TSH, FT4 or FT3. Only FT3 was related to hypothyroid underdosage complaints and neither TSH nor FT4. FT3 was also either low in range or below range in these cases. This clearly shows that for patients under continuous therapy over a long period, FT3 is the relevant measurement and neither of the other two.
I'll inform TUK when the paper is published in final form.
